Dyne Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:DYN Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
07 Jul 26	SellUS$118,050	Atlas Venture Advisors, Inc.	Company	5,000	US$23.61
25 Jun 26	SellUS$48,114	Erick Lucera	Individual	2,362	US$20.37
08 Jun 26	BuyUS$33,880	Brian Posner	Individual	2,000	US$16.94
03 Jun 26	BuyUS$43,700	Brian Posner	Individual	2,500	US$17.48
26 May 26	BuyUS$36,420	Brian Posner	Individual	2,000	US$18.21
20 May 26	BuyUS$42,800	Brian Posner	Individual	2,500	US$17.12
30 Mar 26	BuyUS$34,160	Brian Posner	Individual	2,000	US$17.08
11 Mar 26	BuyUS$38,700	Brian Posner	Individual	2,000	US$19.35
06 Mar 26	BuyUS$45,180	Brian Posner	Individual	3,000	US$15.06

Insider Trading Volume

Insider Buying: DYN insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of DYN?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	508,825	0.268%
Institutions	189,604,847	99.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 31.3%.

Top Shareholders

Top 25 shareholders own 77.67% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
18.7%	T. Rowe Price Group, Inc.	34,849,093	US$603.2m	5.24%	0.05%
6.64%	BlackRock, Inc.	12,404,330	US$214.7m	6.02%	no data
6.42%	Janus Henderson Group Ltd.	11,997,738	US$207.7m	-12.1%	0.08%
6%	FMR LLC	11,206,969	US$194.0m	25.8%	0.01%
3.99%	State Street Investment Management	7,458,263	US$129.1m	12.1%	no data
3.91%	Vanguard Capital Management, LLC	7,299,918	US$126.4m	-0.72%	no data
3.75%	Orbis Investment Management Limited	7,006,542	US$121.3m	3.61%	0.28%
2.47%	TCG Crossover Management, LLC	4,615,144	US$79.9m	0%	2.1%
2.17%	Vanguard Portfolio Management, LLC	4,048,428	US$70.1m	-2.73%	no data
2%	Geode Capital Management, LLC	3,743,427	US$64.8m	6.83%	no data
1.92%	Forbion Capital Partners B.V.	3,586,796	US$62.1m	-6.79%	5.55%
1.84%	Atlas Venture Advisors, Inc.	3,440,720	US$59.6m	-49.4%	9.29%
1.81%	Vestal Point Capital, LP	3,375,000	US$58.4m	-15.6%	1.5%
1.73%	OrbiMed Advisors LLC	3,235,684	US$56.0m	10.9%	0.81%
1.69%	Frazier Life Sciences Management, LP	3,153,082	US$54.6m	0%	1.32%
1.65%	Armistice Capital LLC	3,087,226	US$53.4m	-2.77%	1.46%
1.62%	JP Morgan Asset Management	3,030,151	US$52.5m	-3.29%	no data
1.44%	Perceptive Advisors LLC	2,689,235	US$46.6m	-42.4%	0.78%
1.37%	Logos Global Management, L.P.	2,550,000	US$44.1m	82.1%	2.11%
1.16%	VR Management, LLC	2,173,913	US$37.6m	0%	1.53%
1.14%	Artal Group S.A.	2,129,125	US$36.9m	-4.49%	0.64%
1.11%	Bank of America Corporation	2,063,987	US$35.7m	62.8%	0.01%
1.09%	Franklin Templeton Inc.	2,030,751	US$35.2m	1.85%	0.01%
1.04%	Dimensional Fund Advisors LP	1,946,479	US$33.7m	105%	no data
1.03%	MPM BioImpact LLC	1,922,093	US$33.3m	36.5%	2.38%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/17 05:15
End of Day Share Price	2026/09/16 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dyne Therapeutics, Inc. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Eric Schmidt	Cantor Fitzgerald & Co.
Keay Nakae	Chardan Capital Markets, LLC